Coya Therapeutics grants 10,000 stock options

Coya Therapeutics director Anabella Villalobos received a grant of stock options covering 10,000 shares of common stock.

Rhea-AI Filing Summary

Coya Therapeutics director Anabella Villalobos received a grant of stock options covering 10,000 shares of common stock. The options were granted on January 2, 2026 with an exercise price of $5.65 per share and no cost to receive the award. The filing reports that Villalobos now beneficially owns 10,000 derivative securities directly.

According to the vesting terms, 100% of the option will vest on the first anniversary of the grant date, as long as continuous service is maintained. The options are scheduled to expire on January 2, 2036 if not exercised.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Villalobos Anabella

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Coya Therapeutics (COYA) disclose in this Form 4?

The filing shows that director Anabella Villalobos received a grant of stock options for 10,000 shares of Coya Therapeutics common stock.

What are the key terms of Anabella Villalobos’s stock option grant at COYA?

The stock option covers 10,000 shares of common stock with an exercise price of $5.65 per share, granted on January 2, 2026.

When do the Coya Therapeutics stock options granted to Anabella Villalobos vest?

The filing states that, subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant.

When do the COYA stock options granted to Anabella Villalobos expire?

The options are scheduled to expire on January 2, 2036 if they are not exercised before that date.

How many derivative securities does Anabella Villalobos beneficially own after this transaction?

After the reported grant, Anabella Villalobos beneficially owns 10,000 derivative securities, held as stock options, directly.

Did Anabella Villalobos pay anything to receive these COYA stock options?

The reported price of the derivative security is $0.00, indicating there was no purchase price to receive the stock option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 07:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Villalobos Anabella

(Last) (First) (Middle)

5850 SAN FELIPE ST., SUITE 500

(Street)

HOUSTON TX 77057

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coya Therapeutics, Inc. [ COYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.65	01/02/2026		A		10,000		01/02/2027(1)	01/02/2036	Common Stock, par value $0.0001 per share	10,000	$0.00	10,000	D

Explanation of Responses:

1. Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant.

	/s/ David Snyder, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.